IR Searcher

基本データ

【業種】: 医薬品
【市場】: プライム（内国株式）
【決算期】: 9月
【会社設立】
【上場】: 1995.6
【直近決算日】: 2025-05-08（2Q）
【決算予定日】: 未定

【時価総額】: 320億2400万円
【PBR】: 0.69倍
【配当利回り(予)】: 3.53%

企業概要

富士製薬工業株式会社は、医薬品の開発・製造・販売を主な事業として展開する企業である。
主力製品は、産婦人科領域におけるホルモン剤や、放射線科向けの尿路・血管造影剤などの注射剤で構成され、女性医療分野（更年期障害治療剤や不妊症治療薬）および急性期医療に強みを持つ。
国内では、全国5ヵ所の支店を通じて販売活動を行い、OLIC(Thailand)Limitedとの取引も実施している。
新薬の開発にも注力し、今後は女性向け経口避妊剤「FSN-013」などの上市を目指す姿勢が見て取れる。
企業グループ全体としては、医薬品事業に特化した単一セグメントを形成しており、医療の多様なニーズに応える製品を提供している。

業績修正履歴

年度	タイプ	日付	売上高	営業利益	経常利益	純利益
2023-09	新規	2022-11-10	43,311	4,048	4,088	2,974
2024-09	新規	2023-11-09	48,926	4,907	5,562	4,015
	変更	2023-11-27	48,926(→)	4,907(→)	5,562(→)	6,185(⬆)
	変更	2024-05-09	46,060(⬇)	3,990(⬇)	4,602(⬇)	6,185(→)
今期	新規	2024-11-12	53,360	4,850	4,680	3,380

通期四半期別

売上高

経常利益

純利益

通期四半期別

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
	予想	53,360	4,850	4,680	3,380	139.07	9.09%	8.77%	15.65%	25.00%	5.29%	-45.00%
2025-09	2	24,095	2,305	2,209	1,287	52.83	9.57%	9.17%	12.7%	59.7%	2%	-69.8%
	1	13,000	1,252	1,376	991	40.75	9.63%	10.58%	21%	―	―	-63.8%
2024-09	4	46,138	3,880	4,445	6,146	252.85	8.41%	9.63%	12.8%	0.6%	-1.6%	78.9%
	3	33,155	2,215	2,967	4,910	201.98	6.68%	8.95%	12.5%	-7.8%	8.3%	147.7%
	2	21,388	1,443	2,165	4,257	175.15	6.75%	10.12%	11.2%	-20.9%	-11.8%	140.2%
	1	10,746	-140	-96	2,739	112.73	-1.3%	-0.89%	7.5%	―	―	145.8%
2023-09	4	40,889	3,858	4,519	3,435	141.37	9.44%	11.05%	15.4%	2.1%	21.3%	27.4%
	3	29,482	2,403	2,741	1,982	81.58	8.15%	9.3%	11.4%	-33.5%	-28.4%	-25%
	2	19,225	1,824	2,456	1,772	72.95	9.49%	12.78%	8.5%	-32.7%	-14.3%	-3.3%
	1	9,996	1,190	1,579	1,114	45.88	11.9%	15.8%	5.8%	-23.8%	-0.1%	-0.3%
2022-09	4	35,426	3,777	3,725	2,696	111.01	10.66%	10.51%	4.2%	12.8%	14.6%	10.9%
	3	26,470	3,612	3,828	2,642	108.77	13.65%	14.46%	3.8%	0.3%	6.2%	0%
	2	17,726	2,712	2,866	1,834	75.5	15.3%	16.17%	2.6%	1%	4.7%	-9.3%
	1	9,446	1,562	1,581	1,118	46.05	16.54%	16.74%	1.6%	-8%	-8.7%	-15.8%
2021-09	4	33,990	3,349	3,250	2,432	90.54	9.85%	9.56%	0.6%	6.7%	9%	16.6%
	3	25,498	3,600	3,604	2,641	95.24	14.12%	14.13%	2.4%	62%	67.6%	68.8%
	2	17,277	2,686	2,738	2,021	68.63	15.55%	15.85%	2.2%	54.8%	70%	550.5%
	1	9,295	1,698	1,732	1,328	42.64	18.27%	18.63%	3.6%	61.2%	59.6%	78.3%
2020-09	4	33,793	3,139	2,983	2,085	66.94	9.29%	8.83%	-6.9%	-24.8%	-28.4%	-29.6%
	3	24,899	2,223	2,151	1,565	50.24	8.93%	8.64%	-8.9%	-40.3%	-42.1%	-37.9%
	2	16,905	1,735	1,610	310	9.98	10.26%	9.52%	-8.5%	-29.7%	-35.6%	-81.7%
	1	8,968	1,053	1,085	745	23.92	11.74%	12.1%	-12.7%	-34.4%	-29.1%	-32%
2019-09	4	36,279	4,173	4,169	2,962	97.04	11.5%	11.49%	-4.3%	-5%	-6.8%	-12.2%
	3	27,324	3,726	3,714	2,521	83.17	13.64%	13.59%	-2%	5%	4.4%	-3.3%
	2	18,483	2,467	2,501	1,695	56.66	13.35%	13.53%	2.9%	8.4%	6%	-2.7%
	1	10,279	1,605	1,532	1,096	36.63	15.61%	14.9%	3.2%	-7%	-16%	-15.8%
2018-09	4	37,909	4,391	4,472	3,372	112.68	11.58%	11.8%	7.1%	1.8%	-3.4%	2.2%
	3	27,872	3,547	3,558	2,606	87.1	12.73%	12.77%	7.1%	-0.4%	-6.9%	-3%
	2	17,961	2,275	2,360	1,743	116.49	12.67%	13.14%	3.7%	0%	-6.9%	-2.6%
	1	9,957	1,725	1,824	1,301	86.95	17.32%	18.32%	11.5%	35.4%	19.9%	20.7%
2017-09	4	35,387	4,314	4,628	3,301	220.63	12.19%	13.08%	3.4%	20.9%	42.3%	55.8%
	3	26,016	3,561	3,822	2,688	179.68	13.69%	14.69%	3.9%	24.8%	49.3%	61.4%
	2	17,324	2,274	2,535	1,789	119.6	13.13%	14.63%	2.9%	25%	46.9%	66.8%
	1	8,932	1,274	1,521	1,077	72.05	14.26%	17.03%	0.1%	52.7%	79.4%	97.7%
2016-09	4	34,229	3,568	3,251	2,118	141.64	10.42%	9.5%	8%	9.7%	4.9%	1.2%
	3	25,028	2,853	2,559	1,665	111.36	11.4%	10.22%	8.8%	28.9%	15.6%	18.7%
	2	16,836	1,819	1,725	1,072	71.73	10.8%	10.25%	8.9%	26.3%	16.9%	23.1%
	1	8,927	834	848	545	36.46	9.34%	9.5%	10.7%	1.8%	0.1%	5.6%

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
2025-09	2	11,095	1,053	833	296	12.08	9.49%	7.51%	4.26%	-33.48%	-63.16%	-80.5%
	1	13,000	1,252	1,376	991	40.75	9.63%	10.58%	21%	―	―	-63.8%
2024-09	4	12,983	1,665	1,478	1,236	50.87	12.82%	11.38%	13.82%	14.43%	-16.87%	-14.93%
	3	11,767	772	802	653	26.83	6.56%	6.82%	14.72%	33.33%	181.4%	210.95%
	2	10,642	1,583	2,261	1,518	62.42	14.88%	21.25%	15.31%	149.68%	157.81%	130.7%
	1	10,746	-140	-96	2,739	112.73	-1.3%	-0.89%	7.5%	―	―	145.8%
2023-09	4	11,407	1,455	1,778	1,453	59.79	12.76%	15.59%	27.37%	781.82%	―	2590.74%
	3	10,257	579	285	210	8.63	5.64%	2.78%	17.3%	-35.67%	-70.37%	-74.01%
	2	9,229	634	877	658	27.07	6.87%	9.5%	11.46%	-44.87%	-31.75%	-8.1%
	1	9,996	1,190	1,579	1,114	45.88	11.9%	15.8%	5.8%	-23.8%	-0.1%	-0.3%
2022-09	4	8,956	165	-103	54	2.24	1.84%	-1.15%	5.46%	―	―	―
	3	8,744	900	962	808	33.27	10.29%	11%	6.36%	-1.53%	11.09%	30.32%
	2	8,280	1,150	1,285	716	29.45	13.89%	15.52%	3.73%	16.4%	27.73%	3.32%
	1	9,446	1,562	1,581	1,118	46.05	16.54%	16.74%	1.6%	-8%	-8.7%	-15.8%
2021-09	4	8,492	-251	-354	-209	-4.7	-2.96%	-4.17%	-4.52%	―	―	―
	3	8,221	914	866	620	26.61	11.12%	10.53%	2.84%	87.3%	60.07%	-50.6%
	2	7,982	988	1,006	693	25.99	12.38%	12.6%	0.57%	44.87%	91.62%	―
	1	9,295	1,698	1,732	1,328	42.64	18.27%	18.63%	3.6%	61.2%	59.6%	78.3%
2020-09	4	8,894	916	832	520	16.7	10.3%	9.35%	-0.68%	104.92%	82.86%	17.91%
	3	7,994	488	541	1,255	40.26	6.1%	6.77%	-9.58%	-61.24%	-55.4%	51.94%
	2	7,937	682	525	-435	-13.94	8.59%	6.61%	-3.25%	-20.88%	-45.82%	―
	1	8,968	1,053	1,085	745	23.92	11.74%	12.1%	-12.7%	-34.4%	-29.1%	-32%
2019-09	4	8,955	447	455	441	13.87	4.99%	5.08%	-10.78%	-47.04%	-50.22%	-42.43%
	3	8,841	1,259	1,213	826	26.51	14.24%	13.72%	-10.8%	-1.02%	1.25%	-4.29%
	2	8,204	862	969	599	20.03	10.51%	11.81%	2.5%	56.73%	80.78%	35.52%
	1	10,279	1,605	1,532	1,096	36.63	15.61%	14.9%	3.2%	-7%	-16%	-15.8%
2018-09	4	10,037	844	914	766	25.58	8.41%	9.11%	7.11%	12.08%	13.4%	24.96%
	3	9,911	1,272	1,198	863	-29.39	12.83%	12.09%	14.02%	-1.17%	-6.92%	-4%
	2	8,004	550	536	442	29.54	6.87%	6.7%	-4.62%	-45%	-47.14%	-37.92%
	1	9,957	1,725	1,824	1,301	86.95	17.32%	18.32%	11.5%	35.4%	19.9%	20.7%
2017-09	4	9,371	753	806	613	40.95	8.04%	8.6%	1.85%	5.31%	16.47%	35.32%
	3	8,692	1,287	1,287	899	60.08	14.81%	14.81%	6.1%	24.47%	54.32%	51.6%
	2	8,392	1,000	1,014	712	47.55	11.92%	12.08%	6.11%	1.52%	15.62%	35.1%
	1	8,932	1,274	1,521	1,077	72.05	14.26%	17.03%	0.1%	52.7%	79.4%	97.7%
2016-09	4	9,201	715	692	453	30.28	7.77%	7.52%	6%	-31.12%	-21.81%	-34.25%
	3	8,192	1,034	834	593	39.63	12.62%	10.18%	8.65%	33.76%	13.01%	11.47%
	2	7,909	985	877	527	35.27	12.45%	11.09%	6.98%	58.62%	39.43%	48.45%
	1	8,927	834	848	545	36.46	9.34%	9.5%	10.7%	1.8%	0.1%	5.6%

4554 富士製薬工業 企業サイト Yahooファイナンス 日経新聞 株探 四季報

4554 富士製薬工業　企業サイト　　　Yahooファイナンス　日経新聞　株探　四季報　